Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Stada Arzneimittel AG
Industry Sector: HealthTechnology
CEO: Peter Goldschmidt
Number Of Employees: 10,416
Enterprise Value: $7,105,533,302
PE Ratio: 16.31
Exchange/Ticker 1: Xetra:SAZ
Exchange/Ticker 2: N/A
Latest Market Cap: $5,675,044,370
BioCentury | Sep 20, 2023
Management Tracks
Orwin succeeds Topper as AnaptysBio’s chair
Plus: CDMOs Catalent and Rentschler announce executive changes, and updates from Parexel, Santander, CorriXR and more
BioCentury | Sep 13, 2023
Politics, Policy & Law
IRA list based on politics, pharma veterans say
CMS avoided cancer drugs, prioritized volume over cost to Medicare
BioCentury | Jul 19, 2022
Finance
July 18 Quick Takes: Immunocore raises $140M PIPE
Plus debut for European VC Forty51 Ventures and updates from Simcere, Calliditas and more
BioCentury | Nov 22, 2021
Management Tracks
Mallik resigns as CEO from Rafael
Plus: Connect, Fog, Elucida and Advanz
BioCentury | Nov 6, 2019
Company News
Nov. 5 Company Quick Takes: Takeda licenses MD Anderson CAR NK cell portfolio; plus Myriad, Canbridge, BioCryst-Torii and Strongbridge
BioCentury | May 18, 2018
Clinical News
FDA approves Pfizer's Retacrit, first epoetin alfa biosimilar in U.S.
Items per page:
1 - 10 of 59